Clinical Trial

Neoadjuvant L19IL2/L19TNF- Pivotal Study

Study acronym: Pivotal
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2024 (before its estimated October 2024 completion). Its status may not reflect the trial's current state.
Summary
Phase III, open-label, randomized, controlled multi-center study of the efficacy of L19IL2/L19TNF neoadjuvant intratumoral treatment in Stage III B/C melanoma patients.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2016-10-17; most recent amendment 2024-09-12.
Status change: Recruiting → Active, Not Recruiting 2024-09-02
Trial Details
NCT Number NCT02938299
Lead Sponsor Philogen S.p.A.
Conditions Malignant Melanoma
Enrollment 214 participants
Start Date 2016-07-01
Primary Completion 2024-10 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2024-09-19